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Antibody screening tests are critical tools to identify indi-
viduals infected with HTLV-1 and HTLV-2. However, the
lack of reference panels hinders the ability to evaluate
existing tests and new technologies that aid in the screen-
ing for these agents. For example, some HTLV-2 subtypes
may escape detection by currently available technology.
The World Health Organization, through the support of
the WHO Expert Committee on Biological Standardiza-
tion, is in the process of generating such a reference panel.
This reference panel will best function as a tool for
test assessment only if it consists of specimens repre-
senting the diversity of HTLV-1 and HTLV-2, especially
those subtypes known to present challenges to detection
using serological tests.
There have been challenges sourcing suitable material of
sufficient titre and volume. Initial screening tests carried
out by CBER/FDA and NIBSC, using a range of EIA’s,
have shown a variation in titre of donated material. Two
candidates, HTLV-1a and HTLV-2, have been identified
and are in the process of being formulated into lyophilised
preparations. Such preparations will shortly be distributed
to participating laboratories for testing in a small interna-
tional collaborative study. It is envisaged that additional
panel members will be added as and when appropriate
material is sourced.
This first WHO HTLV antibody reference panel is
expected to be used by blood screening and diagnostic test
developers, blood banks, hospitals and other establishments
performing HTLV serology testing.
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